1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Suppliers list
|
|
| 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Basic information |
Product Name: | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone | Synonyms: | 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone;MAP4343;Pregn-5-en-20-one, 3-methoxy-, (3β)-;5-Pregnen-3B-ol-20-one-17a,21,21,21-d4 3-Methyl Ether;inhibit,microtubule-associated,Microtubule/Tubulin,Pregnenolone,MAP2,tubulin,polymerization,neurites,MAP 4343,MAP4343,Inhibitor,MAP-4343,protein | CAS: | 511-26-2 | MF: | C22H34O2 | MW: | 330.5 | EINECS: | | Product Categories: | | Mol File: | 511-26-2.mol | |
| 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Chemical Properties |
Melting point | 123.5° | alpha | D18 +18° (c = 1.085 in chloroform) | Boiling point | 426.6±45.0 °C(Predicted) | density | 1.04±0.1 g/cm3(Predicted) | storage temp. | Store at -20°C | solubility | DMSO: 25 mg/mL (75.64 mM) |
| 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Usage And Synthesis |
Biological Activity | MAP4343 is a 3-methyl ether derivative of Pregnenolone. It binds to microtubule-associated protein 2 (MAP2) in vitro, stimulates the polymerization of tubulin, enhances neurite extension and protects neurons from neurotoxic agents. | in vitro | MAP4343 (40 μM; 15 or 30 min) stimulates microtubule polymerization in vitro. It stimulates nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells. | in vivo | MAP4343 (12 mg/kg; daily sc for 28 d) improves the recovery of locomotor function after spinal cord injury (SCI) in rats. MAP4343 (4 mg/kg; daily sc for 6 d) increases MAP2 levels in spinal cord after SCI in rats. MAP4343 (4 mg/kg; daily sc for 6 d) increases the size of lumbar spinal motoneurons' dendrite arbours after SCI in rats. < p> Animal Model: | Adult Sprague-Dawley male rats with spinal cord injury | Dosage: | 12 mg/kg | Administration: | Daily sc for 28 days | Result: | Increased the number of animals able to walk with weight-supported plantar steps. Showed forelimb-hindlimb coordination at the end of the study. | |
| 1-[(3S,8S,9S,10R,13R,14S,17S)-3-methoxy-10,13-dimethyl-2,3,4,7,8,9,11, 12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone Preparation Products And Raw materials |
|